Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yuri A. Maricich"'
Publikováno v:
Frontiers in Digital Health, Vol 5 (2023)
Technological progress in digital therapeutics—and, in particular prescription digital therapeutics (PDTs)—has outpaced the processes that the Food and Drug Administration (FDA) uses to regulate such products. Digital therapeutics have entered th
Externí odkaz:
https://doaj.org/article/7a92c4671a8b427f9b4143b2975e2ac9
Autor:
Felicia Forma, Tyler G Knight, Frances P Thorndike, Xiaorui Xiong, Rebecca Baik, Fulton F Velez, Yuri A Maricich, Daniel C Malone
Publikováno v:
ClinicoEconomics and Outcomes Research. 14:537-546
Felicia Forma,1 Tyler G Knight,2 Frances P Thorndike,1 Xiaorui Xiong,1 Rebecca Baik,2 Fulton F Velez,1 Yuri A Maricich,1 Daniel C Malone3 1Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA; 2Labcorp Drug Development, Market Access
Autor:
Fulton F. Velez, Kathryn P. Anastassopoulos, Samuel Colman, Neel Shah, Laura Kauffman, Sean M. Murphy, Charles Ruetsch, Yuri A. Maricich
Publikováno v:
Advances in Therapy. 39:4131-4145
reSET-O, an FDA-authorized prescription digital therapeutic (PDT) delivering cognitive behavioral therapy and contingency management to patients with opioid uRetrospective analysis of healthcare claims data compared all-cause HCRU (across hospital fa
Autor:
Charles Morin, Frances P Thorndike, Joseph M. Ojile, Robert Gerwien, Angela Wendorf, Yuri A Maricich
Publikováno v:
CNS Spectrums. 28:227-228
IntroductionChronic insomnia (CI) often co-occurs with depression and anxiety, and treatment may positively impact mood. This ongoing study collected real-world data on changes in insomnia, depression, and anxiety symptoms among adults with CI treate
Autor:
Charles Ruetsch, Sam Colman, Kathryn Anastassopoulos, Laura Kauffman, Yuri A. Maricich, Fulton Velez
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Fulton F Velez,1 Sam Colman,2 Laura Kauffman,2 Charles Ruetsch,3 Kathryn Anastassopoulos,2 Yuri A Maricich1 1Pear Therapeutics, Inc., Boston, MA, USA; 2Covance Market Access, Gaithersburg, MD, USA; 3Health Analytics, Columbia, MD, USACorrespondence:
Publikováno v:
Hospital Practice. 49:348-355
Purpose To evaluate real-world prescription digital therapeutic (PDT) use and associated clinical outcomes among patients with opioid use disorder (OUD). Patients and methods A real-world observational evaluation of patients who filled either a 12- o
Autor:
Yuri A. Maricich, Edward V. Nunes, Aimee N. C. Campbell, Jeffrey D. Botbyl, Hilary F. Luderer
Publikováno v:
Substance abuse. 43(1)
Autor:
Steven C. Rozycki, Xiaorui Xiong, Paul Walter, Jessica Wright, Hilary F. Luderer, Stephen Braun, Yuri A. Maricich, James Purvis
Publikováno v:
CNS Spectrums. 27:237-238
IntroductionThe opioid epidemic in the United States is getting worse: in 2020 opioid overdose deaths hit an all-time high of 92,183. This underscored the need for more effective and readily available treatments for patients with opioid use disorder
Autor:
Laura Kauffman, Sean M. Murphy, Fulton Velez, Sam Colman, Kathryn Anastassopoulos, Yuri A. Maricich
Publikováno v:
Hospital practice (1995). 49(5)
Outcomes associated with buprenorphine therapy for the treatment of opioid use disorder (OUD) are suboptimal. reSET-O is an FDA-authorized prescription digital therapeutic (PDT) delivering neurobehavioral therapy via mobile devices to patients with O
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 21(4)
Evidence-based behavioral approaches for Opioid Use Disorder (OUD) are resource-intensive and challenging to implement, resulting in the majority of patients not receiving adequate care [1,2]. Medi...